1,731 results on '"Brenner, Malcolm K."'
Search Results
102. Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells
103. Developing T-Cell Therapies for Cancer in an Academic Setting
104. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
105. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
106. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
107. Cancer Gene Therapy : Historical Perspective
108. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant
109. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
110. Is cancer gene therapy an empty suit?
111. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
112. Mouse Models in Bone Marrow Transplantation and Adoptive Cellular Therapy
113. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation
114. Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas
115. Adoptive Transfer of Polyclonal, EBV-Specific Cytotoxic T-Cell Lines for the Prevention and Treatment of EBV-Associated Malignancies
116. Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections
117. Cell-specific transmembrane injection of molecular cargo with gold nanoparticle-generated transient plasmonic nanobubbles
118. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease
119. A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.
120. T-cells resist CD5 CAR mediated fratricide by continuously degrading CD5 protein
121. Engineering T cells to prevent graft-versus-host disease and leukemia relapse following allogeneic stem cell transplantation
122. Chapter 3 - Improving the safety of iPSC-derived T cell therapy
123. Gene Transfer into Hemopoietic Progenitors: Implications for Bone Marrow Transplantation
124. Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
125. Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
126. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia
127. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells
128. Genetic Modification of T Cells
129. Long Term Follow up for the Development of Subsequent Malignancies in Patients Treated with Genetically Modified Immune Effectors
130. Safety and Tolerability of Administering Leukemia-Specific Donor T Cells (mLSTs) after Allogeneic Transplant to Pediatric Patients with AML/MDS
131. Evaluating the Safety and Clinical Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma
132. Phase I Trial of GD2.CAR T Cells Combined with a Novel Interleukin-7 Signal Modulator
133. iCaspase 9 Suicide Gene System
134. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience
135. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation
136. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
137. The Costs and Cost-Effectiveness of Allogeneic Peripheral Blood Stem Cell Transplantation versus Bone Marrow Transplantation in Pediatric Patients with Acute Leukemia
138. Adoptive T cell therapy of cancer
139. Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma
140. Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma
141. Generation of Epstein-Barr virus–specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)
142. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation
143. Nucleofection of DCs to Generate Multivirus-specific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host
144. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes
145. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
146. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
147. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study
148. Remaining Obstacles to the Success of Cancer Gene Therapy
149. Evidence generation and reproducibility in cell and gene therapy research: A call to action
150. Evidence for Zanamivir Resistance in an Immunocompromised Child Infected with Influenza B Virus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.